Spinocerebellar ataxia types 1, 3 and Huntington's disease research hub

A Phase 2 open-label trial to investigate the long term safety of VO659 administered intrathecally in participants with Huntington’s disease and spinocerebellar ataxia type 1 and 3

This study looks at an experimental medicine called VO659 for adults with Huntington’s disease or spinocerebellar ataxia types 1 and 3. Researchers want to find out if giving this treatment directly into the fluid around the spine is safe and well tolerated over a longer period of time.